Multiple Sclerosis, Relapsing-Remitting study: Ozanimod vs Fingolimod
Official title Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis
ClinicalTrials.gov ID: NCT06408259
What this study is testing
What is Ozanimod?
Ozanimod is an investigational medicine, being studied as a potential treatment for multiple sclerosis, relapsing-remitting.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study compares how well ozanimod works and how safe it is compared to fingolimod, looking at drug levels and side effects.
- Who it's for
- Children and adolescents diagnosed with relapsing-remitting multiple sclerosis
- What's involved
- Participants will receive either ozanimod or fingolimod and will have regular medical visits and tests to monitor their condition and drug levels.
- Time commitment
- The study lasts several months, with scheduled visits for medication administration and monitoring.
- Phase 3: a large, late-stage study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 10 to 17
You may be able to join if
- Has a diagnosis of multiple sclerosis (MS) as defined by the 2017 revision of the McDonald Criteria with a relapsing remitting course of disease.
- Meets at least 1 of the following criteria for disease activity: i) At least 1 MS relapse/attack in the previous year prior to screening.
You likely can't join if
- Diagnosis of progressive forms of MS.
- Active or chronic disease of the immune system other than MS.
- Clinically relevant cardiovascular, hepatic, neurological other major systematic disease.
- Other protocol-defined Inclusion/Exclusion criteria apply.
The study team makes the final eligibility decision.
Where it is enrolling
- Sacramento, California, United States
- Tampa, Florida, United States
- Chicago, Illinois, United States
- Louisville, Kentucky, United States
- Milwaukee, Wisconsin, United States
- Melbourne, Victoria, Australia
- Naples, Campania, Italy
- Milan, Lombardy, Italy
- Rome, Roma, Italy
- Braga, Portugal
- Coimbra, Portugal
- Lisbon, Portugal
- Bucharest, Bucharest, Romania
- Vigo, Pontevedra [Pontevedra], Spain
- Seville, Spain
- Valencia, Spain
- Zaragoza, Spain
- Taipei, Taiwan
- Samsun, Turkey (Türkiye)
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 10 years to 17 years. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Sacramento, California, United States; Tampa, Florida, United States; Chicago, Illinois, United States; Louisville, Kentucky, United States; Milwaukee, Wisconsin, United States; Melbourne, Victoria, Australia and 13 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.